The Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical), along with the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND), invites stakeholders from industry, academia, and nonprofit sectors to submit white papers for the development and repurposing of host-directed therapeutics. This call is in anticipation of the upcoming Industry Day on October 29, 2024, which will focus on innovative approaches to prophylaxis, post-exposure prophylaxis, and treatment strategies against a broad spectrum of biological threats.
Host-Directed Therapeutics: A Strategic Focus
Host-Directed Therapeutics (HDTs) represent a transformative approach to prophylaxis and treatment strategies, focusing on enhancing the body’s own defenses rather than directly targeting pathogens. This strategy is particularly crucial in addressing the challenge posed by a wide spectrum of biological threats, including viruses, bacteria, and toxins. The DOD has expressed a strong interest in the late-stage development and repurposing of existing FDA-licensed therapeutics that demonstrate broad-spectrum activity across diverse biological families.
Objectives and Opportunities at the Industry Day
The upcoming Industry Day provides a platform for stakeholders to gain insights into the government’s current and future priorities in HDTs. Participants will have the opportunity to interact with key representatives from JPEO CBRND, BARDA, and JSTO, who will share valuable information on the direction of upcoming projects and research needs.
Moreover, this event serves as a prelude to a more selective presentation opportunity on the following day, October 30, where chosen companies will present their innovative solutions directly to U.S. Government representatives. Selection for this exclusive session will be based on the quality and relevance of responses to the current Request for Information (RFI) concerning host-directed therapeutics.
Key Information for Respondents
For those interested in participating, the RFI outlines critical details:
- Submission Requirements: Proposals should be concise, not exceeding three pages, and must adhere to the provided white paper template.
- Performance Objectives: Ideal candidates for HDTs should demonstrate efficacy either alone or in combination with other licensed therapeutics, with a focus on conditions caused by high-priority agents such as Alphaviruses, Filoviruses, and various toxins.
- Submission Deadline: All responses must be submitted by August 30, 2024, through the designated online portal.
Future Directions and Expectations
The information gathered during this RFI and Industry Day will help shape the government’s approach to acquiring and deploying new medical countermeasures. While participation in this RFI does not guarantee a future solicitation, it opens the door for potential collaborations and contracts, particularly through mechanisms such as Other Transaction Agreements (OTAs) and engagements under the Medical CBRN Defense Consortium (MCDC).
This event is not only a chance to align with the government’s current needs but also an opportunity to contribute to the broader goal of enhancing public health security and preparedness. Entities capable of bringing innovative solutions to the table are strongly encouraged to participate and help drive the future of host-directed therapeutic strategies.
If your company has considered applying for JPEO funding, your federal funding journey starts here.
For additional information about EverGlade Consulting, reach out to: [email protected]